>>Signaling Pathways>> Others>>Lumasiran

Lumasiran (Synonyms: ALN-G01)

Catalog No.GC64379

루마시란(ALN-G01)은 siRNA 제품으로, 글리콜산 산화효소를 대상으로 함으로써 간에서의 옥살산 생성을 줄입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Lumasiran Chemical Structure

Cas No.: 1834610-13-7

Size 가격 재고 수량
1mg
US$529.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2].

Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1[1].

Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2].

[1]. Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282.
[2]. Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384(13):1216-1226.

리뷰

Review for Lumasiran

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lumasiran

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.